CN107325155A - 一种抗氧化超短肽Mapin‑WH2、其制备方法及应用 - Google Patents
一种抗氧化超短肽Mapin‑WH2、其制备方法及应用 Download PDFInfo
- Publication number
- CN107325155A CN107325155A CN201710517366.XA CN201710517366A CN107325155A CN 107325155 A CN107325155 A CN 107325155A CN 201710517366 A CN201710517366 A CN 201710517366A CN 107325155 A CN107325155 A CN 107325155A
- Authority
- CN
- China
- Prior art keywords
- oxidant
- mapin
- peptide
- ultrashort peptide
- ultrashort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 65
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 51
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 49
- 235000006708 antioxidants Nutrition 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 108010024636 Glutathione Proteins 0.000 abstract description 7
- 230000002949 hemolytic effect Effects 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 6
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 6
- 229960003180 glutathione Drugs 0.000 abstract description 6
- 239000002778 food additive Substances 0.000 abstract description 5
- 150000003254 radicals Chemical class 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 235000013373 food additive Nutrition 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 239000000490 cosmetic additive Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000005839 radical cations Chemical class 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- -1 oxygen radical Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- ZSEMWHCVIJETNE-UHFFFAOYSA-N N1=CC=CC2=CC(=C3C=CC=NC3=C12)S(=O)(=O)O.C(C)N1CSC2=C1C=CC=C2 Chemical compound N1=CC=CC2=CC(=C3C=CC=NC3=C12)S(=O)(=O)O.C(C)N1CSC2=C1C=CC=C2 ZSEMWHCVIJETNE-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical class [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical class OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种抗氧化超短肽Mapin‑WH2、其制备方法及应用，属于生物医学技术领域。所述抗氧化超短肽Mapin‑WH2是直链多肽，仅含有5个氨基酸残基，全序列一级结构为：缬氨酸‑亮氨酸‑赖氨酸‑赖氨酸‑半胱氨酸；所述抗氧化超短肽Mapin‑WH2是通过化学合成的方法得到的；所述抗氧化超短肽Mapin‑WH2具有极强的抗氧化活性，相比于临床常用的抗氧化剂谷胱甘肽，清除自由基效果更优，且无溶血性及细胞毒性。本发明中的抗氧化超短肽Mapin‑WH2可以用于抗氧化药物、食品添加剂、抗氧化化妆品原料的制备，并且它的作用可能还不止局限于此。抗氧化超短肽Mapin‑WH2分子量小、结构简单、采用化学合成方法的成本极低，相比临床常用的抗氧化谷胱甘肽具有突出有益的特点。
Description
技术领域
本发明涉及生物医药领域，尤其涉及一种抗氧化超短肽Mapin-WH2、其制备方法及应用。
背景技术
自由基是具有强氧化活性的一组物质，极易发生反应。活性氧自由基不仅会使人体内的脂质与蛋白质发生链式氧化反应导致细胞膜、组织、酶和基因受损，对肌体造成了损害和衰老，而且会促使有关的基因突变，诱发相关的疾病，如动脉硬化症、高血压、类风湿性关节炎、白内障、老年痴呆症、帕金森氏病以及神经退行性病变等。越来越多的医学研究及临床试验证据显示，体内自由基含量越高寿命越短，自由基可谓“万病之源”。
近年来抗氧化在化妆品领域的应用中很广泛。由于皮肤的光老化作用是由于紫外线诱导皮肤细胞产生大量的氧自由基堆积而造成的。现在许多护肤品中加入抗氧化剂，有减少雀斑、防辐射、延缓衰老、调节免疫和提高皮肤自我保护的作用。此外食品中营养成分的氧化反应会产生过氧化物。过氧化物影响食品的营养价值，甚至严重还可导致疾病发生，寻找安全的抗氧化剂以抑制过氧化物产生一直是生化营养学的研究热点。
目前，化工领域常用抗氧化剂多为化学合成物，如BHA、BHT等，虽抗氧化效果良好，但对人体肝、脾、肺有蓄积性致癌作用。临床上常见的抗氧化剂如维生素C、维生素E与谷胱甘肽等。维生素C主要以清除·OH为主，但需大剂量使用才能达到目的，但同时，大剂量维生素C使用容易导致酸中毒；维生素E主要通过抑制细胞膜上的脂质过氧化来达到抗氧化的目的，但长期是用则有潜在的致突变风险。而临床还原型谷胱甘肽的产业化壁垒较高，已被日本协和发酵工业株式会社几乎垄断全球谷胱甘肽的供应，每公斤高达8000美金。同时，现在国内制药企业所用的谷胱甘肽制药原料还不能摆脱进口，谷胱甘肽价格一直居高不下。可见，活性佳、易合成、产量高的新型抗氧化肽已在医疗、食品、化妆品等领域中亟待开发。
发明内容
基于背景技术存在的技术问题，本发明提出了一种抗氧化超短肽Mapin-WH2、其制备方法及应用旨在解决上述技术问题。
本发明采用的技术方案为：一种抗氧化超短肽Mapin-WH2，所述抗氧化超短肽Mapin-WH2为一种直链小肽，含有5个氨基酸残基，全序列一级结构为：缬氨酸-亮氨酸-赖氨酸-赖氨酸-半胱氨酸。
优选的，所述抗氧化超短肽Mapin-WH2的分子量为589.79Da，等电点是9.31。
优选的，所述抗氧化超短肽Mapin-WH2的制备方法，具体步骤如下：
1)多肽肽链的合成；
2)对多肽进行纯化；
3)测定纯化后多肽的分子量；
4)测定多肽的等电点及序列。
优选的，所述抗氧化超短肽Mapin-WH2可用于抗氧化药物、食品添加剂、抗氧化化妆品原料的制备。
本发明的有益效果在于：所述抗氧化超短肽Mapin-WH2具有极强的抗氧化活性，在体外实验中对多种自由基的清除率均在90％以上，且浓度为3mM时，对DPPH自由基、ABTS·+正离子自由基清除率I％可以达到96.75％、95.84％，优于临床常使用的抗氧化制剂——谷胱甘肽。
所述抗氧化超短肽Mapin-WH2具有分子量小、结构简单、溶血活性低、细胞毒性极低、制备方法简单、稳定性高、无蛋白修饰、产量高、纯度高等特点，对比临床用谷胱甘肽成本更低。
所述抗氧化超短肽Mapin-WH2活性强、效价高，因此可将其应用在抗氧化药物、食品或者化妆品添加剂中，可以提高药物、食品或化妆品添加剂的抗氧化效果，具有很好的应用前景。
具体实施方式
下面结合具体实施例对本发明作进一步说明。
实施例1
一种抗氧化超短肽Mapin-WH2，所述抗氧化超短肽Mapin-WH2为一种直链小肽，含有5个氨基酸残基，全序列一级结构为：缬氨酸-亮氨酸-赖氨酸-赖氨酸-半胱氨酸。
优选的，所述抗氧化超短肽Mapin-WH2的制备方法，具体步骤如下：
1、根据超短肽的氨基酸序列：缬氨酸-亮氨酸-赖氨酸-赖氨酸-半胱氨酸，用自动多肽合成仪(型号：433A，Applied Biosystems)合成得到粗多肽；
2、将粗多肽通过HPLC反相柱层析脱盐纯化，通过多次分离纯化、并鉴定其纯度，直到多肽的纯度不低于95％；
HPLC纯化及鉴定方法：将1mg待测样品溶于1mL含有0.1％TFA的超纯水中，若有不溶解的杂质，用0.22μm滤膜过滤，流动相A为0.1％TFA-H2O，流动相B为0.1％TFA-CH3CN(所用洗脱溶剂均需过滤并超声处理，防止色谱柱中产生气泡)，待基线平稳后开始上样，上样量为10μL；色谱柱为硅胶烷基键合相C18柱(4.6mm id×250mm，胶粒大小5μm id，孔径大小为300目)，采用二元流动相梯度洗脱系统，进行梯度洗脱，即在30min内，流动相B在洗脱剂中的含量从0％-80％按线性关系增长，流速1mL/min，检测波长215nm，25℃下测定。
3、使用基质辅助激光解析电离飞行时间质谱(MALDI-TOF)确定其分子量为589.79Da；
测定方法：将纯化后的多肽溶于去离子水中，配置成2μmol/mL的溶液，取1μL与等体积的饱和基质溶液(将α-氰基-4-羟基肉桂酸溶于含0.1％TFA的50％ACN溶液中，制成饱和溶液，离心，取上清液)混合后测定。
4、通过等电聚焦电泳测定纯化后多肽的等电点为9.31，并采用自动氨基酸测序仪测定纯化后多肽的氨基酸序列结构，确定为：缬氨酸-亮氨酸-赖氨酸-赖氨酸-半胱氨酸。
优选的，所述抗氧化超短肽Mapin-WH2可用于抗氧化药物、食品添加剂、抗氧化化妆品原料的制备。
(一)、抗氧化超短肽Mapin-WH2的抗氧化实验：
1.1 DPPH自由基清除活性(DPPH radical scavenging assay)
称取一定量的DPPH(2，2-diphenyl-1-picrylhydrazyl hydrate，Sigma，美国)，用甲醇溶解，配成6×10-5M的溶液，现配现用。将48μl DPPH溶液和2μl样品混合(最终样品与DPPH的质量比为3∶1)，室温下避光静置30min，于517nm处测定吸光值。空白对照组以样品溶解介质代替待测样品。实验做三个平行，紫外分光光度计调零时使用甲醇。
DPPH·清除率(％)＝(AB-AA)/AB×100(AB：空白对照组吸光值；AA：样品组吸光值)。
1.2 ABTS·+自由基正离子清除活性
ABTS(3-ethylbezothiazoline-6-sulfonic acid)(3-乙基苯并噻唑啉-6-磺酸)用PBS缓冲液(pH7.4)配成2mM的ABTS储存液。将ABTS储存液和70mM过硫酸钾(K2S2O8)水溶液按体积比250∶1混合，于室温避光放置15-16h。试验开始前，将ABTS·+释至734nm波长处的吸光值为0.80±0.03。将4μl样品和96μl上述校正过的ABTS·+溶液混合，室温放置10min后，于734nm波长处检测反应液的吸光值。空白对照组为溶解样品所用灭菌去离子水。实验做三个平行。
ABTS·+清除率I(％)＝(AB-AA)/AB×100(AB：空白对照组吸光值；AA：样品组吸光值)。
表1.超短肽Mapin-WH2抗氧化活性
结果如表1所示，抗氧化超短肽Mapin-WH2具有极强的抗氧化活性。在样品浓度为3mM时，Mapin-WH2对DPPH和ABTS·+正离子自由基清除率I％分别可以达到96.75％、95.84％。与临床药物谷胱甘肽具备相当抗氧化活性。故抗氧化超短肽Mapin-WH2将在抗氧化药品、食品等领域具有优秀的开发潜力。
(二)、抗氧化超短肽Mapin-WH2溶血性与细胞毒性测定
2.1溶血性检测。
将采集的健康人血与阿氏液混合抗凝，生理盐水洗涤2次并重悬成107-108cell/ml的悬浮液。上述稀释好的红细胞悬液与溶解于生理盐水的抗氧化超短肽Mapin-WH2样品混合，37℃保温30min，再于1000rpm离心5min，上清液于540nm测吸收值。阴性对照使用生理盐水，阳性对照使用Triton X-100，溶血百分比按以下公式计算：溶血百分比H％＝A样品-A阴性对照/A阳性对照×100％。
表2.抗氧化超短肽Mapin-WH2溶血性
溶血性结果如表2所示，结果表明抗氧化超短肽Mapin-WH2浓度高达160μg/ml时的溶血率只有0.77％。说明Mapin-WH2不具有溶血性，不易引起人体红细胞破裂溶解而对人体产生伤害，因此十分利于其在抗氧化药物、食品或者化妆品添加剂领域进一步的开发应用。
2.2抗氧化超短肽Mapin-WH2细胞毒性检测。
用MTT法检测该组抗氧化超短肽对人皮肤成纤维细胞HFF-1细胞(购于上海细胞库)毒性。先将成纤维细胞于含有15％胎牛血清以及双抗(青霉素和链霉素各100U/ml)的DMEM中培养，待细胞长满后，用0.25％的胰蛋白酶消化下来，用上述培养基洗两次，重新悬浮细胞，细胞计数后将细胞悬浮液100μl加入到96孔细胞培养板中，使每孔细胞数达到105个。加入样品，对照组加入相同体积的灭菌超纯水，置37℃，5％CO2培养箱内培养24h。培养结束后，96孔细胞培养板每孔加入20μl 5mg/ml MTT溶液(用细胞培养PBS缓冲液配制)，继续培养5h，用注射器吸出孔中液体，每孔加入100μl DMSO，用移液枪吹打几次使紫色结晶完全溶解。酶标仪检测光吸收，测定波长490nm，参考波长630nm。
表3.抗氧化超短肽Mapin-WH2对HFF-1细胞的毒性
细胞毒性结果如表3所示，可以看出抗氧化超短肽Mapin-WH2浓度为160μg/ml时的细胞毒性只有14.65％，说明抗氧化超短肽Mapin-WH2对人皮肤成纤维细胞细胞毒性极低，对人体正常皮肤细胞不会产生伤害，因此十分利于其在在抗氧化药物、食品或者化妆品添加剂领域进一步的开发应用。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
序列表
<110>于海宁王慧王义鹏
<120>一种抗氧化超短肽Mapin-WH2、其制备方法及应用
<160> 1
<210> 1
<211>5
<212> PRT
<213>人工序列
<400> 1
Val Leu Lys Lys Cys
1 5
Claims (4)
1.一种抗氧化超短肽Mapin-WH2，其特征在于：所述抗氧化超短肽Mapin-WH2为一种直链小肽，含有5个氨基酸残基，全序列一级结构为：缬氨酸-亮氨酸-赖氨酸-赖氨酸-半胱氨酸。
2.如权利要求1所述的一种抗氧化超短肽Mapin-WH2，其特征在于：所述抗氧化超短肽Mapin-WH2的分子量为589.79Da，等电点是9.31。
3.如权利要求1所述的一种抗氧化超短肽Mapin-WH2的制备方法，具体步骤如下：
1)多肽肽链的合成；
2)对多肽进行纯化；
3)测定纯化后多肽的分子量；
4)测定多肽的等电点及序列。
4.如权利要求1-3任一项所述的一种抗氧化超短肽Mapin-WH2可用于抗氧化药物、食品添加剂、抗氧化化妆品原料的制备。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710517366.XA CN107325155B (zh) | 2017-06-29 | 2017-06-29 | 一种抗氧化超短肽Mapin-WH2、其制备方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710517366.XA CN107325155B (zh) | 2017-06-29 | 2017-06-29 | 一种抗氧化超短肽Mapin-WH2、其制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107325155A true CN107325155A (zh) | 2017-11-07 |
| CN107325155B CN107325155B (zh) | 2020-07-10 |
Family
ID=60198526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710517366.XA Active CN107325155B (zh) | 2017-06-29 | 2017-06-29 | 一种抗氧化超短肽Mapin-WH2、其制备方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107325155B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114315967A (zh) * | 2021-12-31 | 2022-04-12 | 宜肌坊(厦门)生物科技有限公司 | 一种抗氧化肽m8、其制备方法及应用 |
| CN114456234A (zh) * | 2022-03-17 | 2022-05-10 | 中国石油大学(华东) | 抗氧化脂肽及其制备方法和应用 |
| CN114478698A (zh) * | 2021-12-30 | 2022-05-13 | 宜肌坊(厦门)生物科技有限公司 | 抗氧化短肽m5、其制备方法及应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102532266A (zh) * | 2012-01-17 | 2012-07-04 | 梁醒财 | 一种天然抗氧化肽Macrotympanain-A1及其制备方法和应用 |
| CN102988193A (zh) * | 2011-09-19 | 2013-03-27 | 鼎翔生医科技有限公司 | 一种能促进细胞新生及延缓皮肤老化的医学美容多胜肽 |
| WO2013156064A1 (en) * | 2012-04-17 | 2013-10-24 | Activen | Anti-wrinkles cosmetic composition comprising a mu-conopeptide |
| US20150328283A1 (en) * | 2004-09-27 | 2015-11-19 | Technion Research & Development Foundation Limited | Novel antimicrobial agents |
| KR20160116600A (ko) * | 2015-03-30 | 2016-10-10 | 대한민국(농촌진흥청장) | 항산화 활성을 갖는 펩타이드 및 이를 포함하는 조성물 |
-
2017
- 2017-06-29 CN CN201710517366.XA patent/CN107325155B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150328283A1 (en) * | 2004-09-27 | 2015-11-19 | Technion Research & Development Foundation Limited | Novel antimicrobial agents |
| CN102988193A (zh) * | 2011-09-19 | 2013-03-27 | 鼎翔生医科技有限公司 | 一种能促进细胞新生及延缓皮肤老化的医学美容多胜肽 |
| CN102532266A (zh) * | 2012-01-17 | 2012-07-04 | 梁醒财 | 一种天然抗氧化肽Macrotympanain-A1及其制备方法和应用 |
| WO2013156064A1 (en) * | 2012-04-17 | 2013-10-24 | Activen | Anti-wrinkles cosmetic composition comprising a mu-conopeptide |
| KR20160116600A (ko) * | 2015-03-30 | 2016-10-10 | 대한민국(농촌진흥청장) | 항산화 활성을 갖는 펩타이드 및 이를 포함하는 조성물 |
Non-Patent Citations (2)
| Title |
|---|
| SONGYAN ZHANG ET AL.: ""Hainanenins: A novel family of antimicrobial peptides with strong activity from Hainan cascade-frog, Amolops hainanensis"", 《PEPTIDES》 * |
| 李佳宇: "抗氧化肽的研究进展", 《内蒙古石油化工》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478698A (zh) * | 2021-12-30 | 2022-05-13 | 宜肌坊(厦门)生物科技有限公司 | 抗氧化短肽m5、其制备方法及应用 |
| CN114478698B (zh) * | 2021-12-30 | 2023-07-25 | 宜肌坊(厦门)生物科技有限公司 | 抗氧化短肽m5、其制备方法及应用 |
| CN114315967A (zh) * | 2021-12-31 | 2022-04-12 | 宜肌坊(厦门)生物科技有限公司 | 一种抗氧化肽m8、其制备方法及应用 |
| CN114315967B (zh) * | 2021-12-31 | 2023-07-25 | 宜肌坊(厦门)生物科技有限公司 | 一种抗氧化肽m8、其制备方法及应用 |
| CN114456234A (zh) * | 2022-03-17 | 2022-05-10 | 中国石油大学(华东) | 抗氧化脂肽及其制备方法和应用 |
| CN114456234B (zh) * | 2022-03-17 | 2023-06-30 | 中国石油大学(华东) | 抗氧化脂肽及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107325155B (zh) | 2020-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Isolation and characterization of antioxidative peptides from gelatin hydrolysate of Alaska pollack skin | |
| Yu et al. | Immunomodulatory activity of low molecular-weight peptides from Nibea japonica skin in cyclophosphamide-induced immunosuppressed mice | |
| CN105586379B (zh) | 一种具有抑制癌细胞增殖作用的胶原蛋白活性肽的制备方法 | |
| CN107325155A (zh) | 一种抗氧化超短肽Mapin‑WH2、其制备方法及应用 | |
| Suo et al. | Novel angiotensin-converting enzyme inhibitory peptides from tuna byproducts—milts: Preparation, characterization, molecular docking study, and antioxidant function on H2O2-damaged human umbilical vein endothelial cells | |
| JP2003528827A (ja) | カゼイン由来ペプチドおよびその医療用途 | |
| WO2009094850A1 (en) | Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof | |
| CN102205114B (zh) | 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用 | |
| CN107266530A (zh) | 抗氧化超短肽、制备方法及其应用 | |
| CN115089698A (zh) | 改善皮肤的活性肽与干细胞外泌体在药品或化妆品中的应用 | |
| Ma et al. | Rapeseed peptide inhibits HepG2 cell proliferation by regulating the mitochondrial and P53 signaling pathways | |
| Zhang et al. | Bioactive peptides for anticancer therapies | |
| CN104693272A (zh) | 牦牛乳乳清蛋白具有抗氧化活性的三肽及其应用和组合物 | |
| CN101157726A (zh) | 亚血红素短肽化合物及在抗白内障药物制备中的用途 | |
| CN106589068B (zh) | 一种鲷鱼抗氧化多肽及其制备方法 | |
| CN109748951B (zh) | 一种当归抗氧化多肽及其制备方法与应用 | |
| CN100369928C (zh) | 玉米蛋白粉降血压多肽与分离方法及其应用 | |
| CN106317170B (zh) | 一种紫苏籽抗氧化肽及其应用 | |
| CN114907445B (zh) | 一种高抗氧化活性富硒肽及其应用 | |
| CN112125955A (zh) | 一种活性肽、活性肽组合物及其在制备具有抗uv导致皮肤细胞氧化损伤作用的产品中的应用 | |
| CN109232715A (zh) | 一类抗氧化超短肽及其应用 | |
| CN107226841A (zh) | 一类抗氧化超短肽及其应用 | |
| CN115109117A (zh) | 一种多管藻藻红蛋白血管紧张素转化酶抑制肽及其制备方法与应用 | |
| JPH02288899A (ja) | 成熟肝実質細胞増殖因子（ｉ） | |
| CN114315967B (zh) | 一种抗氧化肽m8、其制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180116 Address after: 116024 old chemical building, Dalian University of Technology, Dalian, Liaoning 117 Applicant after: Yu Haining Address before: 215000 Jiangsu city of Changzhou province's new No. 7 North Road Applicant before: Changzhou thousand Biological Technology Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |